Skip to main content
. Author manuscript; available in PMC: 2011 Jun 3.
Published in final edited form as: Cancer Cell. 2011 Apr 12;19(4):541–555. doi: 10.1016/j.ccr.2011.02.006

Figure 1. Breast TAMs Constitutively Express CCL18.

Figure 1

(A) The ratio of a panel of cytokine mRNA in TAMs versus PBMs from patients with breast cancer and IL-4-activated MDMs versus unactivated MDMs from healthy donors, as assayed by qRT-PCR.

(B) The ratio of CCL18 mRNA in TAMs versus PBMs from patients with breast cancer (n = 33) with or without axillary lymph node metastasis, as determined by qRT-PCR (left). Each bar corresponds to mean ± standard deviation (SD) of each individual patient. Representative western blotting for CCL18 in TAMs and PBMs from patients with breast cancer with or without axillary lymph node metastasis (right). β-Actin was used as a loading control.

(C) Immunohistochemical staining of CCL18 in benign cystic fibrosis of the breast, atypical hyperplasia, breast carcinoma in situ, and invasive breast carcinoma.

(D) Serum CCL18 level in the patients with benign breast diseases and invasive breast carcinomas with or without axillary lymph node or distal metastasis, as determined by ELISA. Bars correspond to mean ± SD.

(E) Kaplan-Meier survival curve of patients with breast cancer with lower (≤20 per view of field, n = 405) and higher CCL18-positive TAM counts (>20 per view of field, n = 157; p < 0.001) with a median follow-up period of 45 months. The number of survived patients stratified to the follow-up periods is indicated below the graph.

See also Figure S1.